Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
Oversubscribed financing co-led by HealthCap and EQT Life Sciences…
8 June 2022/by optimusBionical Solutions Bolsters Clinical Services Team
Willington, UK, 7 June 2022 – Bionical Solutions, a leading…
7 June 2022/by optimusVerona Pharma to Host KOL Event on June 16, 2022
LONDON and RALEIGH, N.C., June 06, 2022 (GLOBE NEWSWIRE) -- Verona…
6 June 2022/by optimusWe’d love to hear from you
For more information about optimum Strategic Communications, please get in touch
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
Arix Bioscience: Aura Biosciences prices Nasdaq IPO
/in Client newseTheRNA immunotherapies conference attendance for November 2021
/in Client newsSynaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs
/in Client newsFutura Medical plc Board Appointment
/in Client newsSynendos Therapeutics Appoints Scientific Advisory Board
/in Client news